We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis

By LabMedica International staff writers
Posted on 24 Nov 2025

Extrapulmonary tuberculosis (EPTB) remains difficult to diagnose and treat because it spreads beyond the lungs and lacks easily accessible biomarkers. More...

Despite TB infecting 10 million people yearly, the immune mechanisms driving EPTB have remained unclear. A new study now maps the disease’s molecular activity in blood, identifying immune patterns that could lead to targeted therapies and non-invasive diagnostic tests.

In the collaborative study, researchers at the German Center for Infection Research (DZIF), Braunschweig, Germany) used blood samples from EPTB patients for applying multi-omics profiling, including single-cell RNA sequencing, to chart how immune cells communicate during infection.

The approach revealed complex signaling networks involving interferon and interleukin-1 pathways, as well as activation patterns of T cells and natural killer cells. Based on these molecular interactions, researchers identified three distinct “immunotypes,” each representing a unique disease course. The findings, published in Nature Communications, show that these immunotypes expose new biological mechanisms that shape how EPTB develops and progresses.

In addition to immune profiling, the team constructed gene expression–based biomarkers that accurately differentiated extrapulmonary from pulmonary TB. Current diagnosis of EPTB often requires invasive tissue biopsy; however, the newly identified blood signatures could serve as a future non-invasive diagnostic tool. These markers may help clinicians detect EPTB earlier, classify disease severity, and tailor treatments more precisely.

The investigators emphasize that integrating clinical data was essential to correctly interpret molecular findings and connect them to real patient outcomes. Their blood-based biomarker panel is now being validated in the larger mEX-TB clinical study, marking a step towards translation into clinical practice.

"These findings have the potential to substantially advance the diagnosis and treatment of tuberculosis and to facilitate the development of targeted, personalized therapies," said Dr. Thomas Ulas, a bioinformatician at the DZNE.

Related Links:
DZIF


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
All-in-One Molecular System
AIO M160
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.